nach oben

AIDS and Behavior

Erschienen in:

28.09.2018 | Original Paper

Factors Associated with Awareness of Pre-exposure Prophylaxis for HIV Among Persons Who Inject Drugs in Philadelphia: National HIV Behavioral Surveillance, 2015

verfasst von: Alexis Roth, Nguyen Tran, Brogan Piecara, Seth Welles, Jennifer Shinefeld, Kathleen Brady

Erschienen in: AIDS and Behavior | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Persons who inject drugs (PWID) continue to experience disproportionate HIV burden. Though studies demonstrate PWID find pre-exposure prophylaxis (PrEP) acceptable, awareness and uptake remains low. Data from the 2015 PWID cycle of the National HIV Behavioral Surveillance (n = 612) in Philadelphia, Pennsylvania (USA) were analyzed to evaluate how socio-demographics and behavioral factors impact PrEP awareness. Only 12.4% of PWID surveyed were PrEP-aware and 2.6% reported receiving a prescription. Factors associated with PrEP awareness included having at least some college education (aOR 2.13, 95% CI 1.03, 4.43), sharing paraphernalia (aOR 2.37, 95% CI 1.23, 4.56), obtaining syringes/needles primarily from a syringe exchange program (aOR 2.28, 95% CI 1.35, 3.87), STI testing (aOR 1.71, 95% CI 1.01, 2.89) and drug treatment (aOR 2.81, 95% CI 1.62, 4.87). Accessing prevention and health services increased the odds of being PrEP-aware; however, awareness was low overall. Additional promotion efforts are warranted.

Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS ONE. 2014;9(5):e97596.CrossRefPubMedPubMedCentral

Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2010–2015. HIV Surveillance Supplemental Report 2018; 23(No. 1). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published March 2018. Accessed 28 July 2018.

Centers for Disease Control and Prevention. HIV Surveillance Report, 2016; vol. 28. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published November 2017. Accessed 28 July 2018.

Bastos FI, Strathdee SA. Evaluating effectiveness of syringe exchange programmes: current issues and future prospects. Soc Sci Med. 2000;51(12):1771–82.CrossRefPubMed

Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 2001;15(11):1329–41.CrossRefPubMed

Aspinall EJ, Nambiar D, Goldberg DJ, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):235–48.CrossRefPubMed

Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf. Accessed [17 June 2018.

Substance Abuse and Mental Health Administration, Center for Behavioral Health Statistics and Quality. The DAWN report: highlights of the 2010 drug abuse warning network (DAWN) findings on drug-related emergency department visits. Rockville, MD: 2012. https://www.samhsa.gov/data/sites/default/files/DAWN096/DAWN096/SR096EDHighlights2010.pdf. Accessed 2 May 2018.

Ciccarone D. Heroin in brown, black and white: Structural factors and medical consequences in the US heroin market. Int J Drug Policy. 2009;20(3):277–82.CrossRefPubMed

10.

U.S. Department of Justice, National Drug Intelligence Center. Philadelphia/Camden high intensity drug trafficking area drug market analysis 2011. Washington, D.C.: 2011. https://www.justice.gov/archive/ndic/dmas/Philadelphia-Camden_DMA-2011(U).pdf. Accessed 2 May 2018.

11.

City of Philadelphia. Executive Order No. 4-92. Philadelphia, PA: 1992. https://www.justice.gov/archive/ndic/dmas/Philadelphia-Camden_DMA-2011(U).pdf. Accessed 2 May 2018.

12.

Prevention Point Philadelphia. History of PPP. 2016. https://ppponline.org/about-us/history-ppp. Accessed 4 December 2017.

13.

Philadelphia Department of Public Health. AIDS activities coordinating office surveillance report, 2016. Philadelphia, PA: AIDS Activities Coordinating Office, Department of Public Health, 2016. https://www.phila.gov/health/pdfs/aaco/HIV%20Surveillance%20Report-2016web.pdf. Accessed 2 May 2018.

14.

Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed

15.

Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral

16.

MRC Clinical Trials Unit. The PROUD study: examining the impact on gay men of using pre-exposure prophylaxis (PrEP), study results, key messages, questions and answers. University College London, February 24, 2015. http://www.proud.mrc.ac.uk/results/.

17.

Molina J-M, Capitant C, Spire B, Pialoux G, Chidiac C, Charreau I. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial [23LB]. Presented at: Conference on Retroviruses and Opportunistic Infections; 2015; Seattle, Washington.

18.

Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed

19.

Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral

20.

Escudero DJ, Lurie MN, Kerr T, Howe CJ, Marshall BDL. HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research. J Int AIDS Soc. 2014;17(1):18899.CrossRefPubMedPubMedCentral

21.

Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS ONE. 2012;7(1):e28238.CrossRefPubMedPubMedCentral

22.

Kuo I, Olsen H, Patrick R, et al. Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC. Drug Alcohol Depend. 2016;164:8–13.CrossRefPubMed

23.

Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J. 2017;14(1):40.CrossRefPubMedPubMedCentral

24.

Escudero DJ, Kerr T, Wood E, et al. Acceptability of HIV pre-exposure prophylaxis (PrEP) among people who inject drugs (PWID) in a Canadian setting. AIDS Behav. 2015;19(5):752–7.CrossRefPubMedPubMedCentral

25.

Stein M, Thurmond P, Bailey G. Willingness to use HIV pre-exposure prophylaxis among opiate users. AIDS Behav. 2014;18(9):1694–700.CrossRefPubMedPubMedCentral

26.

Roth AM, Goldshear JL, Martinez-Donate AP, Welles S, Chavis M, Van Der Pol B. Reducing missed opportunities: pairing sexually transmitted infection screening with syringe exchange services. Sex Transm Dis. 2016;43(11):706–8.CrossRefPubMed

27.

Shrestha R, Karki P, Altice FL, et al. Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. Drug Alcohol Depend. 2017;173:107–16.CrossRefPubMedPubMedCentral

28.

Walters SM, Rivera AV, Starbuck L, et al. Differences in awareness of pre-exposure prophylaxis and post-exposure prophylaxis among groups at-risk for HIV in New York State: New York City and Long Island, NY, 2011–2013. J Acquir Immune Defic Syndr. 2017;75:S383–91.CrossRefPubMed

29.

Kelley CF, Kahle E, Siegler A, et al. Applying a PrEP continuum of care for men who have sex with men in Atlanta. Georgia. Clin Infect Dis. 2015;61(10):1590–7.CrossRefPubMed

30.

Behavioral Surveillance Team NCHSTP/DHAP-SE/BCSB. Model Surveillance Protocol, Injecting Drug Users (NHBS-IDU3) Heterosexuals at Increased Risk of HIV (NHBS-HET3). National HIV Behavioral Surveillance System Round 3; 2011.

31.

Gallagher KM, Sullivan PS, Lansky A, Onorato IM. Behavioral surveillance among people at risk for HIV infection in the US: the National HIV Behavioral Surveillance System. Public Health Rep. 2007;122:32–8.CrossRefPubMedPubMedCentral

32.

Lansky A, Abdul-Quader AS, Cribbin M, et al. Developing an HIV behavioral surveillance system for injecting drug users: the National HIV Behavioral Surveillance System. Public Health Rep. 2007;122:48–55.CrossRefPubMedPubMedCentral

33.

Heimer R, Abdala N. Viability of HIV-1 in syringes: implications for interventions among injection drug users. AIDS Read. 2000;10(7):410–7.PubMed

34.

aidsmap. Why is injecting drug use a risk for HIV transmission? NAM Publications, October 1, 2011. http://www.aidsmap.com/Why-is-injecting-drug-use-a-risk-for-HIV-transmission/page/1324128/. Accessed Jan 31 2018.

35.

Murphy S, Kelley MS, Lune H. The health benefits of secondary syringe exchange. J Drug Issues. 2004;34(2):245–68.CrossRef

36.

Valente TW, Foreman RK, Junge B, Vlahov D. Needle-exchange participation, effectiveness, and policy: syringe relay, gender, and the paradox of public health. J Urban Health. 2001;78(2):340–9.CrossRefPubMedPubMedCentral

37.

Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychol. 2003;22(4):332–9.CrossRefPubMed

38.

Latkin CA. Outreach in natural settings: the use of peer leaders for HIV prevention among injecting drug users’ networks. Public Health Rep. 1998;113(Suppl 1):151–9.PubMedPubMedCentral

39.

Garfein RS, Golub ET, Greenberg AE, et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS. 2007;21(14):1923–32.CrossRefPubMed

40.

Latkin CA, Donnell D, Metzger D, et al. The efficacy of a network intervention to reduce HIV risk behaviors among drug users and risk partners in Chiang Mai, Thailand and Philadelphia, USA. Soc Sci Med. 2009;68(4):740–8.CrossRefPubMed

41.

Chan PA, Glynn TR, Oldenburg CE, et al. Implementation of preexposure prophylaxis for human immunodeficiency virus prevention among men who have sex with men at a New England sexually transmitted diseases clinic. Sex Transm Dis. 2016;43(11):717–23.CrossRefPubMedPubMedCentral

42.

Petroll AE, Walsh JL, Owczarzak JL, et al. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21(5):1256–67.CrossRefPubMedPubMedCentral

43.

Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104–10.CrossRefPubMedPubMedCentral

Titel: Factors Associated with Awareness of Pre-exposure Prophylaxis for HIV Among Persons Who Inject Drugs in Philadelphia: National HIV Behavioral Surveillance, 2015
verfasst von: Alexis Roth
Nguyen Tran
Brogan Piecara
Seth Welles
Jennifer Shinefeld
Kathleen Brady
Publikationsdatum: 28.09.2018
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 7/2019
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-018-2293-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Factors Associated with Awareness of Pre-exposure Prophylaxis for HIV Among Persons Who Inject Drugs in Philadelphia: National HIV Behavioral Surveillance, 2015

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

A Review of Approaches Used to Increase Awareness of Pre-exposure Prophylaxis (PrEP) in the United States

Vulnerable at Each Step in the PMTCT Care Cascade: High Loss to Follow Up During Pregnancy and the Postpartum Period in Tanzania

Promoting ‘Equitable Access’ to PrEP in Australia: Taking Account of Stakeholder Perspectives

Increases in Pre-exposure Prophylaxis Use and Decreases in Condom Use: Behavioral Patterns Among HIV-Negative San Francisco Men Who have Sex with Men, 2004–2017

Representations of Pre-exposure Prophylaxis, Informal Antiretroviral Medication Use for HIV Prevention, and Diversion on Geosocial Networking Apps among Men Who Have Sex with Men

Integrated Next Step Counseling (iNSC) for Sexual Health and PrEP Use Among Young Men Who Have Sex with Men: Implementation and Observations from ATN110/113

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin